SOPHIE KHANAHMADI

Pharmaceutical Supply Chain. H.R.2213: Medical Supply Chain Resiliency Act. Issues related to the 340(b) program. H.R.1492/S.832: EPIC Act of 2025.

Issues related to USTR/trade.

Proposed changes to the FY 2026 Medicare Hospital Inpatient Prospective Payment System and Long-Term Care Hospitals proposed rule.

Health issues. Medicare/Medicaid issues. H.R.5269: RESULTS Act.

General Medicare and Medicaid Issues.

Prescription drug payment reform. Pharmaceutical Supply Chain.

Health programs impacting MDMA. Issues related to medical devices. Issues related to FDA approval of medical devices. Issues related to sterilization of medical devices. Barriers to market access for medical device companies. Issues related to the coverage for FDA Breakthrough products and the H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medical Device User Fee Amendments (MDUFA) implementation. Issues related to physician fee schedule. Issues related to coverage of telehealth services. Issues related to regulation and reimbursement of artificial intelligence in healthcare. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC). Supply chain issues. Cyber security issues related to consumer and health data privacy. TCET Issues related to the New Technology Add on Payment (NTAP).

Access to and reimbursement of medical devices in Medicare program. Issues related to Medicare coverage reform. Issues related to Medicare coverage for digital health technologies. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers. Issues related to CMS expansion of prior authorization requirements for medical procedures.

General health care coverage issues. Healthcare reform.

Reimbursement issues for prescription drugs. Drug pricing reform. Vaccine Access. Food and Drug Administration legislative and regulatory issues.

Fiduciary PBM. Lower Costs, More Transparency Act. HSA Provisions. S.2355: Patients Deserve Price Tags Act.

General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.

Medicare/Medicaid issues. Medicaid drug rebate program. Prescription drug pricing, including MDRP Substance Use Disorder Policy. Implementation of Inflation Reduction Act of 2022. H.R.946: ORPHAN Cures Act. Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically. Provide guidance and advice regarding mental health, public health and regulatory reform.

Medicaid State-Directed Payments and Intergovernmental Transfers.

Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs. Drug pricing reform. Food and Drug Administration legislative and regulatory issues.

Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs.

Issues related to access to rare disease therapies, diagnosis and testing. Issues related to FDA modernization and rare disease drug development. Issues related to the Accelerated Approval Program. Issues related to Public Law No. 117-169 - The Inflation Reduction Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025.

Pharmaceutical Supply Chain. H.R.2213: Medical Supply Chain Resiliency Act. Issues related to the 340(b) program. H.R.1492/S.832: EPIC Act of 2025.

Issues related to USTR/trade.

Proposed changes to the FY 2026 Medicare Hospital Inpatient Prospective Payment System and Long-Term Care Hospitals proposed rule.

Coverage and reimbursement for innovative lab-developed tests. H.R.5269: RESULTS Act.

Health programs impacting MDMA. Issues related to medical devices. Issues related to FDA approval of medical devices. Issues related to sterilization of medical devices. Barriers to market access for medical device companies. Issues related to the coverage for FDA Breakthrough products and the H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medical Device User Fee Amendments (MDUFA) implementation. Issues related to physician fee schedule. Issues related to coverage of telehealth services. Issues related to regulation and reimbursement of artificial intelligence in healthcare. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC). Supply chain issues. Cyber security issues related to consumer and health data privacy. TCET Issues related to the New Technology Add on Payment (NTAP).

Access to and reimbursement of medical devices in Medicare program. Issues related to Medicare coverage reform. Issues related to Medicare coverage for digital health technologies. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers. Issues related to CMS expansion of prior authorization requirements for medical procedures.

Healthcare-related legislative and regulatory issues.

General health care coverage issues. Healthcare reform.

Reimbursement issues for prescription drugs. Drug pricing reform. Vaccine Access. Food and Drug Administration legislative and regulatory issues.

Fiduciary PBM. Lower Costs, More Transparency Act. HSA Provisions. S.2355: Patients Deserve Price Tags Act.

General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.

Medicare/Medicaid issues. Medicaid drug rebate program. Prescription drug pricing, including MDRP Substance Use Disorder Policy. Implementation of Inflation Reduction Act of 2022. H.R.946: ORPHAN Cures Act. Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically. Provide guidance and advice regarding mental health, public health and regulatory reform.

Coverage and reimbursement for innovative lab-developed tests.

Medicaid State-Directed Payments and Intergovernmental Transfers.

General Medicare and Medicaid Issues.

Prescription drug payment reform. Pharmaceutical Supply Chain.

Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs.

Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs. Drug pricing reform. Food and Drug Administration legislative and regulatory issues.

Issues related to USTR/trade.

Pharmaceutical Supply Chain. H.R.2213: Medical Supply Chain Resiliency Act. Issues related to the 340(b) program. H.R.1492/S.832: EPIC Act of 2025.

Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs. Drug pricing reform. Food and Drug Administration legislative and regulatory issues.

Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs.

Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs. Drug pricing reform. Food and Drug Administration legislative and regulatory issues.

Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs.

Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs. Drug pricing reform. Food and Drug Administration legislative and regulatory issues.

Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs.

Issues related to access to rare disease therapies, diagnosis and testing. Issues related to FDA modernization and rare disease drug development. Issues related to the Accelerated Approval Program. Issues related to Public Law No. 117-169 - The Inflation Reduction Act of 2022. Issues related to alternative funding programs. Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R.1262/S.932 - Give Kids a Chance Act of 2025.

Proposed changes to the FY 2026 Medicare Hospital Inpatient Prospective Payment System and Long-Term Care Hospitals proposed rule.

Access to and reimbursement of medical devices in Medicare program. Issues related to Medicare coverage reform. Issues related to Medicare coverage for digital health technologies. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers. Issues related to CMS expansion of prior authorization requirements for medical procedures.

Health programs impacting MDMA. Issues related to medical devices. Issues related to FDA approval of medical devices. Issues related to sterilization of medical devices. Barriers to market access for medical device companies. Issues related to the coverage for FDA Breakthrough products and the H.R. 1691 Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Medical Device User Fee Amendments (MDUFA) implementation. Issues related to physician fee schedule. Issues related to coverage of telehealth services. Issues related to regulation and reimbursement of artificial intelligence in healthcare. Issues related to Transitional Coverage for Emerging Technologies (TCET)(CMS-3421-NC). Supply chain issues. Cyber security issues related to consumer and health data privacy. TCET Issues related to the New Technology Add on Payment (NTAP).

Pediatric Review Reauthorization. H.R.946/S.1862: ORPHAN Cures Act. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932: Give Kids a Chance Act of 2025.

Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry.

Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry.

Healthcare-related legislative and regulatory issues.

Reimbursement issues for prescription drugs. Drug pricing reform. Vaccine Access. Food and Drug Administration legislative and regulatory issues.

General health care coverage issues. Healthcare reform.

Fiduciary PBM. Lower Costs, More Transparency Act. HSA Provisions. S.2355: Patients Deserve Price Tags Act.

General health care coverage and reimbursement for prescription drugs. Drug pricing reform. Food and Drug Administration legislative and regulatory issues.

General health care coverage and reimbursement for prescription drugs.

General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.

Medicare/Medicaid issues. Medicaid drug rebate program. Prescription drug pricing, including MDRP Substance Use Disorder Policy. Implementation of Inflation Reduction Act of 2022. H.R.946: ORPHAN Cures Act. Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically. Provide guidance and advice regarding mental health, public health and regulatory reform.

Prescription drug payment reform. Pharmaceutical Supply Chain. General Medicare and Medicaid Issues.

Prescription drug payment reform. Pharmaceutical Supply Chain. General Medicare and Medicaid Issues.

Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs. Drug pricing reform. Food and Drug Administration legislative and regulatory issues.

Healthcare-related legislative and regulatory issues impacting the biotechnology, pharmaceutical, and consumer health industry. General health care coverage and reimbursement for prescription drugs. Drug pricing reform. Food and Drug Administration legislative and regulatory issues.